Stocks and Investing Stocks and Investing
Fri, November 11, 2022
Thu, November 10, 2022

Madhu Kumar Maintained (ARCT) at Strong Sell with Increased Target to $14 on, Nov 10th, 2022


Published on 2024-10-28 00:05:47 - WOPRAI, Madhu Kumar
  Print publication without navigation


Madhu Kumar of Goldman Sachs, Maintained "Arcturus Therapeutics Holdings Inc." (ARCT) at Strong Sell with Increased Target from $8 to $14 on, Nov 10th, 2022.

Madhu has made no other calls on ARCT in the last 4 months.



There are 6 other peers that have a rating on ARCT. Out of the 6 peers that are also analyzing ARCT, 1 agrees with Madhu's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Gena Wang of "Barclays" Upgraded from Sell to Hold and Increased Target to $25 on, Wednesday, November 2nd, 2022


These are the ratings of the 5 analyists that currently disagree with Madhu


  • Yigal Nochomovitz of "Citigroup" Upgraded from Hold to Strong Buy on, Thursday, November 3rd, 2022
  • Pete Stavropoulos of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $44 on, Wednesday, November 2nd, 2022
  • John Abbott of "Wells Fargo" Maintained at Buy with Decreased Target to $98 on, Wednesday, August 10th, 2022
  • Steven Seedhouse of "Raymond James" Downgraded from Hold to Sell on, Wednesday, August 10th, 2022
  • Pete Stravropoulos of "Cantor Fitzgerald" Initiated at Buy and Held Target at $39 on, Tuesday, July 19th, 2022
Contributing Sources